



Funded by the Horizon 2020 Framework Programme  
of the European Union

## Nottingham a major partner in a new European Academic Liver Disease Network

Adverse liver reaction from medications are rare, but have serious consequences including life threatening acute liver failure. The European Cooperation in Science and Technology (COST) has launched a new network involving 51 partners across 16 Countries in Europe and worldwide to bring together scientists, clinicians, industry and regulators to focus on key challenges in this area.



Experts from a diverse disciplines including drug development, clinical practice and medicines regulation have formed the 'Prospective European Drug-induced Liver Injury Network' Chaired by Prof Raul Andrade, University of Malaga and Prof Guruprasad Aithal, Gastrointestinal and Liver Disorder Theme lead of NIHR Nottingham BRC at the University of Nottingham and Nottingham University Hospitals NHS Trust, as the Vice-Chair on the COST Action Management Committee. Dr Jane Grove, Assistant Professor, Nottingham Digestive Diseases Centre, University of Nottingham is also the co-leader of one of the working groups.

*'Pro-Euro DILI network provides an excellent opportunity for scientists, clinicians, small and medium enterprises, pharma and regulators across Europe and beyond to get together and make co-ordinated efforts to address some of the most obdurate problems related to drug-induced liver injury'*

Prof Guruprasad Aithal

The COST Action has created a multi-disciplinary network hosting conferences, training schools and researcher exchange placements will promote a highly innovative and translational research programme striving to pre-empt and prevent Drug-Induced Liver Injury (DILI) over the next four years.

For further information about the COST Action, please visit:  
<https://www.cost.eu/actions/CA17112#tabs|Name:overview>